H.C. Wainwright analyst Swayampakula Ramakanth downgraded Elevation Oncology (ELEV) to Neutral from Buy with a 36c price target down from $1.0, after the company entered into a definitive merger agreement with Concentra Biosciences that includes a proposal to be acquired for a purchase price of 36c per share in cash.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELEV:
- Elevation Oncology downgraded to Hold from Buy at TD Cowen
- Elevation Oncology downgraded to Market Perform from Outperform at William Blair
- Elevation Oncology Merges with Concentra Biosciences
- Elevation enters into agreement to be acquired by Concentra for 36c per share
- Elevation Oncology: Hold Rating Amid Strategic Uncertainty and Financial Constraints